


P R O G R A M



*Metabolic syndrome,
type II diabetes,
and atherosclerosis congress*

Marrakesh • Morocco • May 19th - 23rd, 2004



International Task Force
for Prevention of
Coronary Heart Disease



Under the aegis of His Majesty the King Mohammed VI

Metabolic syndrome,
type II diabetes,
and atherosclerosis congress

Organized by



International Task Force
for Prevention of
Coronary Heart Disease



SOCIÉTÉ MAROCAINE
D'ATHÉROSCLÉROSE

Under the aegis of



alfediam
ASSOCIATION DE LANGUE
FRANÇAISE POUR L'ÉTUDE
DU DIABÈTE ET DES
MALADIES MÉTABOLIQUES



INTERNATIONAL
ATHEROSCLEROSIS
SOCIETY



NSFA
www.nafa.asso.fr



ESFE

Sponsored by



AstraZeneca



FOURNIER
PHARMA



Kowa



MERCK



MSD



Schering-Plough



Pfizer

sanofi~synthelabo



Under the aegis of
His Majesty
the King Mohammed VI



Welcome address

Dear Friends and Colleagues,

On behalf of the "Metabolic syndrome, type II diabetes, and atherosclerosis congress", it is our great pleasure to cordially welcome all the participants to the "Palais des Congrès" of Marrakesh.

We have made every effort to set up a program highly susceptible to interest both physicians and academic researchers, covering the most recent new data on the topics of this congress.

We hope that you will enjoy the scientific events of this congress. We would like to thank the high-level lecturers and all the authors who submitted very interesting papers and posters. To give more opportunities to share our knowledge, posters will be displayed for the whole duration of the meeting.

Our wishes are that you can enjoy and never forget this exciting scientific event.

Welcome to Marrakesh,

Professor Jean-Charles FRUCHART

President, International Task Force
of Coronary Heart Disease

President Elect, International Atherosclerosis Society

Directeur du Département Athérosclérose
et UR545 INSERM

Institut Pasteur de Lille - France

Contents

Program
at a glance 4

Program

Thursday 20th 6

Friday 21st 10

Saturday 22nd 14

General
information 18

The Congress
from A to Z 19

Wednesday 19 th	Thursday 20 th	Friday 21 st	Saturday 22 nd	Sunday 23 rd	
<ul style="list-style-type: none"> Attendees arrival 	08.45 - 10.15 <ul style="list-style-type: none"> Sympo 1 Metabolic syndrome, type II diabetes, and atherosclerosis: Genetics 	08.45 - 10.15 <ul style="list-style-type: none"> Sympo 3 Metabolic syndrome, type II diabetes, and atherosclerosis: Drugs 	08.45 - 10.15 <ul style="list-style-type: none"> Sympo 5 Metabolic syndrome, type II diabetes, and atherosclerosis: Biology 	<ul style="list-style-type: none"> Attendees departure 	
	10.15 - 10.45 <ul style="list-style-type: none"> Coffee break - Poster exhibition Visit of the exhibition 	10.15 - 10.45 <ul style="list-style-type: none"> Coffee break - Poster exhibition Visit of the exhibition 	10.15 - 10.45 <ul style="list-style-type: none"> Coffee break - Poster exhibition Visit of the exhibition 		10.45 - 05.30 <ul style="list-style-type: none"> SMA-NSFA Meeting
	10.45 - 12.15 <ul style="list-style-type: none"> Supported symposium Fournier 	10.45 - 12.15 <ul style="list-style-type: none"> Supported symposium AstraZeneca 	10.45 - 12.15 <ul style="list-style-type: none"> Supported symposium Sanofi-Synthelabo 		
	12.30 - 02.00 <ul style="list-style-type: none"> Hot topics • Lunch debate 1 or lunch 	12.30 - 02.00 <ul style="list-style-type: none"> Hot topics • Lunch debate 2 or lunch 	12.30 - 02.00 <ul style="list-style-type: none"> Lunch 		
	02.00 - 03.30 <ul style="list-style-type: none"> Sympo 2 Metabolic syndrome, type II diabetes, and atherosclerosis: Epidemiology 	02.00 - 03.30 <ul style="list-style-type: none"> Sympo 4 Metabolic syndrome, type II diabetes, and atherosclerosis: Clinical studies and trials 	02.00 - 02.45 <ul style="list-style-type: none"> State of the art lecture 		
	03.30 - 04.00 <ul style="list-style-type: none"> Coffee break - Poster exhibition Visit of the exhibition 	03.30 - 04.00 <ul style="list-style-type: none"> Coffee break - Poster exhibition Visit of the exhibition 	02.45 - 05.30 <ul style="list-style-type: none"> Poster exhibition 		
	04.00 - 05.30 <ul style="list-style-type: none"> Supported symposium Merck KGaA 	04.00 - 05.30 <ul style="list-style-type: none"> Supported symposium Kowa 			
<ul style="list-style-type: none"> Congress opening ceremony 			<ul style="list-style-type: none"> Congress closing dinner 		

Lectures

Lectures have been coded as follows:

- **AL** (Academic Lectures - Academic symposia)
- **LL** (Laboratory Lectures - Supported symposia)
- **HT** (Hot Topics - Academic symposia)

Detailed program ►

08.45 am ACADEMIC SYMPOSIUM I
10.15 am METABOLIC SYNDROME, TYPE II DIABETES, AND ATHEROSCLEROSIS: GENETICS

Co-chair by: M. Naruszewicz (Poland) & M. Simionescu (Romania)

- 08.45 am** Opening remarks M. Naruszewicz (Poland)
- 08.50 am** Human genetic variation and complex human traits D. Cox (USA) **AL-1**
- 09.10 am** Treasure your exceptions clues for identification of novel targets for common diseases M. Hayden (Canada) **AL-2**
- 09.30 am** Interaction between genotype and environmental factors in determining risk of CHD: a common variant in the uncoupling protein 2 gene as an example S. Humphries (UK) **AL-3**
- 09.50 am** Molecular understanding of atherosclerosis- interaction of oxidized LDL and its receptor (TBA) **AL-4**
- 10.10 am** Closing remarks M. Simionescu (Romania)
- 10.15 am** **Coffee break - Poster exhibition - Visit of the exhibition - ("SALLE ROYALE" ROOM)**

10.45 am SUPPORTED SYMPOSIUM FOURNIER
12.15 pm ELEVATED CHD RISK IN TYPE II DIABETES: IS HYPERGLYCEMIA THE CULPRIT?

Co-chair by: J.-C. Fruchart (France) & J. Davignon (Canada)

- 10.45 am** Opening remarks J.-C. Fruchart (France)
- 10.50 am** Atherogenic dyslipidemia: what is the culprit? F. Sacks (USA) **LL-1**
- 11.10 am** Hyperglycemia versus metabolic syndrome in type II diabetes A. Chait (USA) **LL-2**
- 11.30 am** Metabolic syndrome and CHD risk: beyond type II diabetes J.-P. Després (Canada) **LL-3**
- 11.50 am** Lessons from the trials and clinical implications P. Barter (Australia) **LL-4**
- 12.10 pm** Closing remarks J. Davignon (Canada)
- 12.30 pm** **Lunch ("LA PALMERAIE" RESTAURANT) or Hot topics - Lunch debate I** (see following page)
- 01.45 pm**



Low HDL-C can be a hidden danger

unless you know where to look

Patients with Metabolic Syndrome and/or Type 2 diabetes may be at serious risk of a CHD event due to their typical abnormal lipid profile: low HDL-C, raised TG, normal or moderately raised LDL-C.

Raising low HDL-C with a fibrate has been proven to significantly reduce the risk of CHD in these patients.

Lipanthyl® (fenofibrate):

- Significantly raises HDL-C to a target level of 40mg/dl
- Significantly lowers TG (40-55%)
- Reduces elevated LDL-C (20-35%)

So the next time you see an abnormal lipid profile characterised by low HDL-C, prescribe Lipanthyl®.



There's more to it than you think

12.30 pm
02.00 pm **HOT TOPICS – LUNCH DEBATE I**

Chair by: F. Berthezène (France)

- 12.30 pm Opening remarks F. Berthezène (France)
- 12.35 pm Metabolism of apolipoprotein AV and its regulation J. Fruchart-Najib (France) **HT-1**
- 12.55 pm Association of apoA5 -1131 T/C genetic variation with coronary artery disease - postprandial prospect? A. Csazar (Hungary) **HT-2**
- 01.15 pm Apo AV truncation as a cause of dominant severe hypertriglyceridemia : Apo AV Lyon Ph. Moulin (France) **HT-3**
- 01.35 pm Major autosomic dominant hypertriglyceridemia in two families with apoA-V mutation. Kinetic studies B. Verges (France) **HT-4**
- 01.55 pm Closing remarks F. Berthezène (France)

02.00 pm
03.30 pm **ACADEMIC SYMPOSIUM 2
METABOLIC SYNDROME, TYPE II DIABETES, AND ATHEROSCLEROSIS: EPIDEMIOLOGY**

Co-chair by: J. Chapman (France) & J. Bonnet (France)

- 02.00 pm Opening remarks J. Chapman (France)
- 02.05 pm New data from the PROCAM study G. Assmann (Germany) **AL-5**
- 02.25 pm Risk assessment: Metabolic syndrome and diabetes A. Tonkin (Australia) **AL-6**
- 02.45 pm The double jeopardy of the metabolic syndrome M. Taskinen (Finland) **AL-7**
- 03.05 pm Coronary risk and its reduction in the metabolic syndrome G. Steiner (Canada) **AL-8**
- 03.25 pm Closing remarks J. Bonnet (France)

03.30 pm
04.00 pm **Coffee break - Poster exhibition - Visit of the exhibition - ("SALLE ROYALE" ROOM)**

04.00 pm
05.30 pm **SUPPORTED SYMPOSIUM MERCK KGaA
RAISING HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C):
THE CRITICAL TARGET IN DYSLIPIDAEMIA TODAY?**

Co-chair by: G. Assmann (Germany) & J.-C. Fruchart (France)

- 04.00 pm Chairman's introduction G. Assmann (Germany)
- 04.05 pm Beyond statin monotherapy: what do the trials tell us? B. Brewer (USA) **LL-5**
- 04.25 pm Raising HDL-C: the key to atherosclerosis regression? J. Chapman (France) **LL-6**
- 04.45 pm HDL-C and the vessel wall: critical issues in atherosclerosis G. Assmann (Germany) **LL-7**
- 05.05 pm Raising HDL-C: the critical target in dyslipidemia today E. Bruckert (France) **LL-8**
- 05.25 pm Summary J.-C. Fruchart (France)

DYSLIPIDEMIA

NEW



+26%
HDL ↑

Niaspan
The HDL Raiser

* Goldberg et al. Am J Cardiol 2000;85:1100-1105

Merck CardioMetabolic Care

Niaspan™ 375 mg Prolonged-Release tablets, Niaspan™ 500 mg Prolonged-Release tablets, Niaspan™ 750 mg Prolonged-Release tablets, Niaspan™ 1000 mg Prolonged-Release tablets **Indication:** Treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia, characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol, and in patients with primary hypercholesterolaemia. Niaspan should be used in patients in combination with HMG-CoA reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA reductase inhibitor monotherapy is inadequate. Niaspan can be used as monotherapy only in patients who do not tolerate statins. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Niaspan. **Dosage:** Take at bedtime, after a low-fat snack. Initiate treatment by gradually escalating the dose. Recommended dose escalation: Week 1: 1x 375mg, Week 2: 1x 500mg, Week 3: 1x 750mg at bedtime, Weeks 4-7: 2x 500mg at bedtime. After week 7, titrate dose according to response and tolerance. Dose may be increased to 1500mg daily, and subsequently to 2000mg daily. Do not increase daily dose by more than 500mg in a four week period. The maximum dose is 2000mg per day. **Maintenance dose:** 1000mg (two 500mg tablets) to 2000mg (two 1000mg tablets) once daily at bedtime. The tablet strengths are not interchangeable. Women may respond at lower doses than men. **Children:** Not recommended. **Elderly:** No dose adjustment necessary. **Renal impairment:** Caution is advised. **Hepatic impairment:** See contra-indications and special warning and precautions for use. **Contra-indications:** Hypersensitivity to nicotinic acid or to any of the excipients; significant liver dysfunction; active peptic ulcer disease; arterial bleeding. **Special Warning and Precautions for Use:** **Special Warning – Liver** - Niaspan must not be replaced with other nicotinic acid preparations. Caution is advised in patients consuming substantial quantities of alcohol and/or have a history of liver disease. Elevated liver enzymes were observed under Niaspan therapy. Elevations were reversible upon discontinuation. Liver tests must be performed periodically. **Skeletal muscle** - Single cases of rhabdomyolysis in patients on combined therapy with Niaspan and HMG-CoA reductase inhibitors have been reported. Physicians should monitor patients for signs of rhabdomyolysis and determine CPK especially in patients with pre-disposing factors for rhabdomyolysis. **Liver and Skeletal muscle** - The prescribing information of the HMG-CoA reductase inhibitor should be consulted. **Precautions** - Closely observe patients with a history of jaundice, hepatobiliary disease, or peptic ulcer. Monitor diabetic or potentially diabetic patients - adjustment of diet and/or hypoglycaemic therapy may be necessary. Caution in patients with unstable angina or in acute phase of myocardial infarction, particularly when also receiving vasoactive drugs. Caution in patients predisposed to gout. Small dose-related reductions in platelet count and increases in prothrombin have been reported: carefully evaluate patients undergoing surgery. During concomitant administration with anti-coagulants, closely monitor prothrombin time and platelet counts. Small dose-related reductions in phosphorous levels have been reported. Monitoring of patients at risk of hypophosphatemia is recommended. **Pregnancy and Lactation:** Should not be taken by pregnant women unless strictly necessary. Must not be used by breast-feeding women. **Interactions:** Concomitant alcohol and hot drinks may increase undesirable flushing and itching and should be avoided around the time of Niaspan intake. Nicotinic acid may potentiate the blood-pressure-lowering effect of ganglionic blocking agents or vasoactive drugs. Bile acid sequestrants may bind Niaspan and should not be taken at the same time. Potential interference with tests for plasma or urinary catecholamines and urinary glucose. **Side effects:** Very common - flushing. Common - diarrhoea; nausea; vomiting; abdominal pain; dyspepsia; itching; rash. Uncommon - dizziness; headache; rapid heart beat; palpitations; shortness of breath; sweating; pain; asthenia; chills; peripheral oedema; changes in laboratory tests: AST, ALT, alkaline phosphatase, total bilirubin, LDH, amylase; glucose; uric acid; reduction in platelet count; prolongation of prothrombin time; reduction in phosphorus. Rare - decreased glucose tolerance; insomnia; fainting; low blood pressure; drop in blood pressure when sitting up; rhinitis; muscle disorders; muscle pain; muscle weakness. Very rare - anorexia. **Presentation:** 7, 14, 28, 56, 98 prolonged-release tablets in blisters. 100 prolonged-release tablets in a bottle. Not all containers or pack sizes may be registered or marketed. **Date of Preparation:** March 2004 **Full prescribing information available on request from:** Merck KGaA, Frankfurter Str. 250, 64271 Darmstadt, Germany **Date of Printing:** March 2004



08.45 am ACADEMIC SYMPOSIUM 3
10.15 am METABOLIC SYNDROME, TYPE II DIABETES, AND ATHEROSCLEROSIS: DRUGS

Co-chair by: R. Paoletti (Italy) & H. Greten (Germany)

- 08.45 am** Opening remarks R. Paoletti (Italy)
- 08.50 am** Statins in the treatment of the metabolic syndrome:
a polyvalent drug for a complex syndrome J. Davignon (Canada) **AL-9**
- 09.10 am** The Metabolic Syndrome, Insulin Resistance, and Inflammation:
a VA-HIT Perspective S. Robins (USA) **AL-10**
- 09.30 am** Do anti-diabetic agents affect arterial biology? P. Libby (USA) **AL-11**
- 09.50 am** Nuclear receptors controlling the Metabolic Syndrome B. Staels (France) **AL-12**
- 10.10 am** Closing remarks H. Greten (Germany)
- 10.15 am** **Coffee break - Poster exhibition - Visit of the exhibition - ("SALLE ROYALE" ROOM)**
10.45 am

10.45 am SUPPORTED SYMPOSIUM ASTRAZENECA
12.15 pm METABOLIC SYNDROME: FROM DIAGNOSIS TO EMERGING THERAPIES

Co-chair by: J.-C. Fruchart (France) & F. Berthezène (France)

- 10.45 am** Opening remarks J.-C. Fruchart (France)
- 10.50 am** The metabolic syndrome: definition E. Bruckert (France) **LL-9**
- 11.10 am** Diabetes, metabolic syndrome and atherosclerosis:
understanding the link J. Betteridge (UK) **LL-10**
- 11.30 am** Low HDL-C: how important? J. Kastelein (Netherlands) **LL-11**
- 11.50 am** Treatment options for prevention and management
of metabolic syndrome M. Farnier (France) **LL-12**
- 12.10 pm** Closing remarks F. Berthezène (France)
- 12.30 pm** **Lunch ("LA PALMERAIE" RESTAURANT) or Hot topics - Lunch debate 2** (see following page)
01.45 pm

12.30 pm
02.00 pm **HOT TOPICS – LUNCH DEBATE 2**

- HDL therapy: new vistas *C. Sirtori (Italy)* **HT-5**
- Role of adipophilin on lipid accumulation in human macrophages *M. Rouis (France)* **HT-6**
- New insights into lipolytic PPAR activation *J. Plutzky (USA)* **HT-7**

02.00 pm
03.30 pm **ACADEMIC SYMPOSIUM 4**
METABOLIC SYNDROME, TYPE II DIABETES, AND ATHEROSCLEROSIS:
CLINICAL STUDIES AND TRIALS

Co-chair by: A. Steinmetz (Germany) & M. Rosseneu (Belgium)

- 02.00 pm** Opening remarks *A. Steinmetz (Germany)*
- 02.05 pm** Collaborative AtoRvastatin Diabetes Study (CARDS) *P. Durrington (UK)* **AL-13**
- 02.25 pm** Lipid intervention with the combination of simvastatin and ezetimibe in the prevention of aortic valve stenosis and atherosclerotic disease: is lower LDL better? *T. Pedersen (Norway)* **AL-14**
- 02.45 pm** CETP, key player in the atherogenic dyslipidemia of metabolic syndrome *J. Chapman (France)* **AL-15**
- 03.05 pm** Reversing the metabolic syndrome in non human primates *B. Hansen (USA)* **AL-16**
- 03.25 pm** Closing remarks *M. Rosseneu (Belgium)*

03.30 pm **Coffee break - Poster exhibition - Visit of the exhibition**
04.00 pm ("SALLE ROYALE" ROOM)

04.00 pm
05.30 pm **SUPPORTED SYMPOSIUM KOWA**
MEMORIAL SYMPOSIUM FOR PROFESSOR YUICHIRO GOTO -
EFFECTS OF STATINS AND MECHANISM OF ACTION ON ATHEROSCLEROSIS

Co-chair by: G. Assmann (Germany) & Y. Saito (Japan)

- 04.00 pm** Opening remarks *G. Assmann (Germany)*
- 04.05 pm** Statins, PPAR α and lipid profile *J.-C. Fruchart (France)* **LL-13**
- 04.25 pm** Effect of Pitavastatin on smooth muscle migration *Y. Saito (Japan)* **LL-14**
- 04.45 pm** Biological Atlas of Insulin Resistance (BAIR) *J. Scott (UK)* **LL-15**
- 05.05 pm** Pitavastatin modulates lipid raft function in neuron and vascular endothelial cell: Novel molecular basis of pleiotropic effect of statins *T. Kodama (Japan)* **LL-16**
- 05.25 pm** Closing remarks *Y. Saito (Japan)*

08.45 am **ACADEMIC SYMPOSIUM 5**

10.15 am **METABOLIC SYNDROME, TYPE II DIABETES, AND ATHEROSCLEROSIS: BIOLOGY**

Co-chair by: C. Calvo (Chile) & A. Adlouni (Morocco)

- 08.45 am Opening remarks C. Calvo (Chile)
- 08.50 am Endothelial gene expression: effects of TG rich lipoproteins A. Catapano (Italy) **AL-17**
- 09.10 am The role of sterol transporters in atherosclerosis S. Fojo (USA) **AL-18**
- 09.30 am High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease A. von Eckardstein (Switzerland) **AL-19**
- 09.50 am Adiponectin and inflammatory markers in patients with coronary artery disease A. Olsson (Sweden) **AL-20**
- 10.10 am Closing remarks A. Adlouni (Morocco)

10.15 am **Coffee break - Poster exhibition - Visit of the exhibition - ("SALLE ROYALE" ROOM)**
10.45 am

10.45 am **SUPPORTED SYMPOSIUM SANOFI-SYNTHÉLABO**
12.15 pm **THE ENDOCANNABINOID SYSTEM:
A NEW TARGET FOR CARDIOVASCULAR RISK FACTOR MANAGEMENT**

Co-chair by: J.-C. Fruchart (France) & H. Greten (Germany)


- 10.45 am Opening remarks J.-C. Fruchart (France)
- 10.50 am The endocannabinoid (ECB) system: a new player in the reinforcement and energy control functions U. Pagotto (Italy) **LL-17**
- 11.15 am Selective cannabinoid receptor antagonism and its role in the management of obesity/metabolic syndrome J.-P. Després (Canada) **LL-18**
- 11.40 am The importance of treating obesity and achieving smoking cessation in managing cardiovascular risk J.-P. Bassand (France) **LL-19**
- 12.05 pm Closing remarks H. Greten (Germany)

12.30 pm **Lunch ("LA PALMERAIE" RESTAURANT)**
01.45 pm

02.00 pm **STATE OF THE ART LECTURE**
02.45 pm **ADIPOCYTOKINES AND METABOLIC SYNDROME** Y. Matsuzawa **SOTA**

02.45 pm **Coffee break - Poster exhibition - Visit of the exhibition - ("SALLE ROYALE" ROOM)**
05.30 pm

08.00 pm **Congress closing dinner - Departure by bus opposite each hotel at 08.00 pm sharp. Return by bus to each hotel at around 11.30 pm**



sanofi~synthelabo
Because health matters

10.45 am
05.30 pm

SMA-NSFA MEETING • CARDIOVASCULAR PREVENTION FORUM

10.45 am
12.15 pm

SYMPOSIUM - CARDIOVASCULAR RISK ASSESSMENT

Co-chair by: L. Chabraoui (Morocco) & J.-F. Toussaint (France)

- 10.45 am Opening remarks L. Chabraoui (Morocco)
- 10.50 am Limits of application of the strategy of "the high cardiovascular risk" A. Hafidi (Morocco) **AL-21**
- 11.15 am Which emerging risk factors are candidates to be major risk factors? Ph. Giral (France) **AL-22**
- 11.40 am Integration of risk markers in clinical practice for cardiovascular assessment J. Bonnet (France) **AL-23**
- 12.05 pm Closing remarks J.-F. Toussaint (France)

02.00
03.30 pm

SYMPOSIUM - CARDIOVASCULAR PREVENTION

Co-chair by: F. Marouane (Morocco) & E. Bruckert (France)

- 02.00 pm Opening remarks F. Marouane (Morocco)
- 02.05 pm Management of diabetes in France in 2001:
The ENTRED Study data A. Penforis, A. Fagot-Campagna (France) **AL-24**
- 02.30 pm Are all people with diabetes having a high cardiovascular risk? A. Chraibi, A. Hafidi (Morocco) **AL-25**
- 02.55 pm Prevalence, treatment and control of hypertension in Morocco S. Abir (Morocco) **AL-26**
- 03.20 pm Closing remarks E. Bruckert (France)

04.00
04.45 pm

SYMPOSIUM - PLAQUE RUPTURE AND ACUTE CORONARY SYNDROME

Co-chair by: A. Chraibi (Morocco) & J. Chapman (France)

- 04.00 pm Opening remarks A. Chraibi (Morocco)
- 04.05 pm Recent developments in vascular plaque imaging by MRI J.-F. Toussaint (France) **AL-27**
- 04.20 pm Prevention and management of acute coronary syndromes C. Abdelkhirane (Morocco) **AL-28**
- 04.35 pm Closing remarks J. Chapman (France)

BRAINSTORM SESSION

04.45
05.30 **Recommendations on assessment and management of cardiovascular disease**

- ▶ 08.00 pm **Congress closing dinner - Departure by bus opposite each hotel at 08.00 pm sharp. Return by bus to each hotel at around 11.30 pm**

CONGRESS VENUE

- ▶ **Palais des Congrès de Marrakech**
Avenue de France - Marrakech - 40000 (Maroc)
Tel: +212 44 33 91 00 - Fax: +212 44 33 91 20/21

- ▶ **Opening hours of the congress welcome desk:**
Main entrance of the Marrakesh congress center / Level 0
Wednesday May 19th 04.00 pm - 07.00 pm
Thursday May 20th 08.00 am - 06.00 pm

- Friday May 21st 08.00 am - 06.00 pm
Saturday May 22nd 08.00 am - 06.00 pm

ORGANIZATION COMMITTEE

- ▶ **During the congress:**
Palais des Congrès de Marrakech - "Salle Reda 4" room / Level - I

- ▶ **After the conference:**
MSAC 2004 C/o PLB. Organisation
Hôtel de Créquy - 15, rue de Pontoise - 78100 Saint-Germain-en-Laye - France
Tel: +33 (0) 1 39 04 24 24 - Fax: +33 (0) 1 39 04 24 25
• Managing Director: • Pascal Le Borgne / p.leborgne@agence-plb.com
• Congress Coordinators:
- Fabien Duval-Alexandre / f.duval@agence-plb.com / Direct phone number: +33 (0) 1 39 04 07 15
- Caroline Fuentes-Colas / c.fuentescolas@agence-plb.com / Direct phone number: +33 (0) 1 39 04 24 20

SCIENTIFIC COMMITTEE

- ▶ **During the congress:**
Palais des Congrès de Marrakech - "Salle Reda 4" room / Level - I

- ▶ **After the conference:**
• Pr Jean-Charles Fruchart / Jean-Charles.Fruchart@pasteur-lille.fr
Caroline Branlant (assistant) / Caroline.Branlant@pasteur-lille.fr
Atherosclerosis Department and UR545 Inserm - Institut Pasteur de Lille
1, rue du Professeur Calmette - 59019 Lille Cedex - France
Tel: +33 (0) 3 20 87 79 32 - Fax: +33 (0) 3 20 87 73 19 / 73 60

REGISTRATION FEES

- ▶ **The registration fees to the congress include the conference documents (program and abstract book) as well as admission to:**
- all congress oral sessions and the poster exhibition
 - the exhibition area from May 20th to May 22nd
 - the lunches on May 20th, 21st and 22nd
 - the coffee breaks on May 20th, 21st and 22nd (Saturday afternoon excepted)
 - The cocktail following the congress opening ceremony on Wednesday May 19th at the Marrakesh congress center
 - the congress closing dinner on Saturday May 22nd at the restaurant "Le Borj Bladi" - Fantasia show

► **ABSTRACT BOOK**

This book is available to all registered delegates.
Abstracts have been coded according to the type of lecture (see the "Lectures" section).

► **BADGES**

All participants are kindly requested to wear badge at all times throughout the congress and during social events.

► **BUS SHUTTLES**

Free bus shuttles will run between the different hotels (mentioned in this programme) and the Marrakesh Congress Center located on the Avenue de France.
Departure opposite each hotel (please ask for the time table at the congress welcome desk).

► **COFFEE BREAKS**

They will be served in the "Salle Royale" room twice a day during the following time schedule:

Thursday May 20th from 10.15 to 10.45 am and from 03.30 to 04.00 pm
Friday May 21st from 10.15 to 10.45 am and from 03.30 to 04.00 pm
Saturday May 22nd from 10.15 to 10.45 am

► **CONGRESS CLOSING DINNER**

All registered delegates are invited to attend the congress closing dinner on **Saturday May 22nd** at the restaurant "Le Borj Bladi" - Fantasia show.

Departure by bus opposite each hotel at 08.00 pm sharp.

Arrival at the restaurant at about 08.25 pm.
Return by bus at around 11.30 pm.

► **EXHIBITION** – "Salle Royale" room - Level 0

Opening hours of the exhibition

Thursday May 20th 8.30 am – 6.00 pm
Friday May 21st 8.30 am – 6.00 pm
Saturday May 22nd 8.30 am – 5.30 pm

List of exhibitors

• **AstraZeneca**
 • **Fournier Pharma**
 • **Merck KGaA**

► **HOTELS**

The organization committee has arranged accommodation on request for delegates in the following hotels located at a walking distance from the congress center (listed in alphabetical order):

Hotel	Address	Phone	Fax
ATLAS MEDINA	Avenue de France	+212 44 33 99 00	+212 44 43 33 08
KEMPINSKI MANSOUR EDDAHBI	Avenue de France	+212 44 33 91 00	+212 44 33 91 20
LA MAMOUNIA*	Avenue Bab Jdid	+212 44 44 44 09	+212 44 44 46 60
LE MERIDIEN N'FIS*	Avenue de France	+212 44 44 87 72	+212 44 33 94 05
SOFITEL MARRAKECH*	Rue Aroun Errachid	+212 44 42 56 00	+212 44 42 05 05

* Daily free bus shuttles will run between these hotels and the Marrakesh congress center.

► **INSURANCE**

The organizers cannot be held liable for medical, travel or personal claims. Participants are strongly advised to seek personal insurance coverage.

► **LECTURES**

Please note that lectures have been coded as follows:

- **AL (Academic Lectures - Academic symposia)**
- **LL (Laboratory Lectures - Supported symposia)**
- **HT (Hot Topics - Academic symposia)**

► **LUNCHES**

The lunches on May 20th, 21st and 22nd are included in the registration fees.

On Thursday May 20th and Friday May 21st, lunches will take place at:

- **"LA PALMERAIE" RESTAURANT - THE KEMPINSKI HOTEL MANSOUR EDDAHBI**
12.30 • 01.45 pm
- **"SALLE DES MINISTRES" (hot-topics – lunch debates) / Level -1**
12.30 • 02.00 pm - Warning: number of lunch boxes limited

On Saturday May 22nd, lunches will only be served at:

- **"LA PALMERAIE" RESTAURANT - THE KEMPINSKI HOTEL MANSOUR EDDAHBI**
12.30 • 01.45 pm

▶ **MESSAGES**

Should you wish to leave a message to another participant, please report to the congress welcome desk. Please regularly consult the message board located near the congress welcome desk.

▶ **NO SMOKING**

Please remember that smoking is prohibited within the “Salle des Ministres” and “Salle des Ambassadeurs” conference rooms and in the poster and exhibition areas.

▶ **OFFICIAL LANGUAGES**

The official languages of the congress are English and French.

Academic symposia, supported symposia and hot topics will be simultaneously translated (the SMA/NSFA meeting on Saturday May 22nd excepted).

▶ **POSTER EXHIBITION – “SALLE ROYALE” ROOM - level 0**

Posters are displayed for the whole duration of the congress. They must be set up in the poster room located level -I (“Salle Royale” room). Please set up your poster according to the poster number you have been given (refer to the list in the poster exhibition area). Hanging fixtures are available in this area. Authors are requested to mount their poster as of 8.00 am on Thursday May 20th, 2004.

Opening hours of the poster exhibition
Thursday May 20th 8.30 am – 6.00 pm
Friday May 21st 8.30 am – 6.00 pm
Saturday May 22nd 8.30 am – 5.30 pm

Poster abstracts
 (see the abstract book)

▶ **PREVIEW ROOM / BUSINESS CENTER – “SALLE REDA 3” ROOM - level -1**

In order to insure the easy running of the congress, all speakers must proceed to the “Preview room / Business center” in advance in order to have their oral presentation loaded. A computer technician will be in the preview room (“Salle Reda 3” room, level -1) at the following times:

Thursday May 20th 8.00 am - 6.00 pm
Friday May 21st 8.00 am - 6.00 pm
Saturday May 22nd 8.00 am - 5.30 pm
 (closing between 12.30 and 01.30 pm – lunch time)

▶ **TOURIST OFFICE IN MARRAKESH**

For more information regarding sightseeing tours and places of interest please contact the Marrakesh Tourist Office at: Place Abd el-Moumen Ben Ali - Marrakesh 40000 - Morocco
 Tel. +212 44 43 61 31 - Fax +212 44 43 60 57
 Opening hours: Mo - Fr. / 8.30 am-12.00 pm and 02.30 pm-06.30 pm • Saturdays: 9.00 am - 12.00 pm

NOTES



Jusqu'à **50%**
de baisse du LDL-c
à la dose de 10 mg⁽¹⁾

MEDICUS PARIS DCRES 4099-2004/04.

PRENEZ LE POUVOIR SUR LE **LDL-cholestérol**


CRESTOR® 10 mg
rosuvastatine

(1) Résumé des caractéristiques du produit CRESTOR®
Fabriqué sous licence Shionogi & Co Ltd, Osaka, Japon.

CRESTOR® 10 mg, comprimé pelliculé, CRESTOR® 20 mg, comprimé pelliculé. COMPOSITION : CRESTOR® 10 mg : rosuvastatine 10,00 mg (sous forme de rosuvastatine calcique). CRESTOR® 20 mg : rosuvastatine 20,00 mg (sous forme de rosuvastatine calcique). Pour un comprimé pelliculé. Excipients : lactose monohydraté, cellulose microcristalline, phosphate tricalcique, crospovidone, stéarate de magnésium. Pelliculage : lactose monohydraté, hypromellose, triacétate de glycérol, dioxyde de titane (E171), oxyde de fer rouge (E172). **FORME PHARMACEUTIQUE :** comprimé pelliculé. CRESTOR® 10 mg : comprimé rond, de couleur rose, gravé "ZD4522" et "10" sur une seule face. CRESTOR® 20 mg : comprimé rond, de couleur rose, gravé "ZD4522" et "20" sur une seule face. **DONNÉES CLINIQUES : INDICATIONS THÉRAPEUTIQUES :** hypercholestérolémies pures (type IIa incluant les hypercholestérolémies familiales hétérozygotes) ou dyslipidémies mixtes (type IIb) en complément d'un régime lorsque la réponse au régime et aux autres traitements non pharmacologiques (exercice, perte de poids) n'est pas suffisante. Hypercholestérolémie familiale homozygote, en complément d'un régime et d'autres traitements hypolipidémisants (notamment l'aphérese des LDL) ou lorsque ces traitements ne sont pas appropriés.

Voir suite des mentions légales au dos